Form 4 for INCY Incyte
Accepted 2026-09-17 16:04:37 ET · period of report 2026-09-15 · accession 0001205703-26-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 16:04 | 2026-09-15 | INCY | CAGNONI PABLO J | Pres, Gbl Head of R, D | M - OptEx | $66.39 | +23.2K | 206.4K | +13% | +$1.54M |
| DMT | 2026-09-17 16:04 | 2026-09-15 | INCY | CAGNONI PABLO J | Pres, Gbl Head of R, D | S - Sale+OE | $120.49 | -23.2K | 183.2K | -11% | -$2.80M |
| DMT | 2026-09-17 16:04 | 2026-09-15 | INCY | CAGNONI PABLO J | Pres, Gbl Head of R, D | M - OptEx | $0.00 | -23.2K | 18.5K | -56% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 2,957 | $61.76 | 186,157 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-15 | M | A | 4,551 | $61.18 | 190,708 | D | — | — | |
| 3 | Common | Common Stock | 2026-09-15 | M | A | 6,477 | $64.25 | 197,185 | D | — | — | |
| 4 | Common | Common Stock | 2026-09-15 | M | A | 9,233 | $71.93 | 206,418 | D | — | — | |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 9,233 | $120.50 | 197,185 | D | — | — | |
| 6 | Common | Common Stock | 2026-09-15 | S | D | 13,985 | $120.49 | 183,200 | D | — | — | (F1) This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2026-09-15 | M | D | 2,957 | $0.00 | 4,225 | D | $61.76 · — to 2033-07-13 | 2,957 Common Stock | (F2) The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2026-09-15 | M | D | 4,551 | $0.00 | 4,551 | D | $61.18 · — to 2034-01-17 | 4,551 Common Stock | (F3) Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2026-09-15 | M | D | 6,477 | $0.00 | 20,356 | D | $64.25 · — to 2034-07-14 | 6,477 Common Stock | (F4) The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
| 10 | Derivative | Employee Stock Option (right to buy) | 2026-09-15 | M | D | 9,233 | $0.00 | 18,466 | D | $71.93 · — to 2035-01-16 | 9,233 Common Stock | (F5) Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. |